Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically.

J L Frater1, K F McCarron, J P Hammel

  • 1Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44106, USA.

American Journal of Clinical Pathology
|November 17, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Cell death & disease·2024
Same author

Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.

Antimicrobial agents and chemotherapy·2023
Same author

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia.

Antimicrobial agents and chemotherapy·2022
Same author

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.

Antimicrobial agents and chemotherapy·2022
Same author

Comments regarding "Bone mineral density and complete blood count ratios in children and adolescents with obesity" by Bala MM and Bala KA.

European review for medical and pharmacological sciences·2022
Same author

Socio-cultural similarity with host population rather than ecological similarity predicts success and failure of human migrations.

Proceedings. Biological sciences·2022

Atypical chronic lymphocytic leukemia (aCLL) shows distinct morphological, clinical, and immunophenotypic features compared to typical CLL. These atypical features indicate a more aggressive disease course and higher progression probability.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoid malignancy.
  • Atypical CLL (aCLL) presents with distinct morphological characteristics.
  • Understanding aCLL features is crucial for prognosis and treatment.

Purpose of the Study:

  • To compare the clinical and immunophenotypic features of aCLL with typical CLL.
  • To identify markers associated with a more aggressive clinical behavior in aCLL.
  • To establish distinguishing criteria for aCLL.

Main Methods:

  • Comparative analysis of 17 aCLL cases against 24 clinical and 58 immunophenotypic CLL controls.
  • Evaluation of morphological, clinical (WBC, platelet counts), and flow cytometric data (CD5, CD23, CD79b, sIg).

Related Experiment Videos

  • Assessment of CD38 expression and trisomy 12 in aCLL cases.

    • Main Results:

    • aCLL patients exhibited higher mean WBC counts and lower platelet counts than controls.
    • aCLL cases showed a significantly higher probability of disease progression.
    • Increased CD23 expression was observed in aCLL compared to CLL controls; no significant differences in CD5, CD79b, or sIg.
    • CD38 expression and trisomy 12 were infrequent in the tested aCLL cases.

    Conclusions:

    • aCLL can be reliably distinguished from typical CLL morphologically, clinically, and immunophenotypically.
    • Atypical morphological features in CLL are indicative of aggressive clinical behavior.
    • Immunophenotypic analysis, particularly CD23 expression, aids in differentiating aCLL.